BRCA1/2 mutations account for less than 30% of ovarian cancer patients [33], and those who did not met the criteria for secondary platinum-sensitive relapse were excluded, as were those on maintenance therapy with PARPi or bevacizumab. This evidence concerns the gene BRCA1 and ovarian carcinoma.